Oncology Market Research: What Pharma Marketers Get Wrong

Oncology market research is the structured process of gathering intelligence about cancer treatment markets, including physician prescribing behaviour, patient experience, payer dynamics, and competitive positioning. Done well, it gives pharmaceutical and biotech marketers the grounding they need to make product, messaging, and launch decisions that hold up under commercial pressure.

Done poorly, it produces beautifully formatted decks that nobody acts on, filled with findings that were already assumed before the first interview was conducted.

I have spent time across industries where the stakes of getting research wrong are mostly commercial. In oncology, the stakes are different. A positioning decision built on flawed research does not just cost revenue. It can mean a genuinely effective treatment reaches fewer patients than it should, or that a product enters a market with a message that alienates the very clinicians it needs to convince. That changes how seriously you take the methodology.

Why Oncology Is a Research Category of Its Own

Oncology is not a single market. It is a collection of highly specific, often small, and scientifically complex sub-markets organised around tumour type, line of therapy, biomarker status, and treatment modality. A research design that works for a primary care cardiovascular product will not work here.

When I was running agency teams across 30 industries, one of the discipline we worked hardest to instil was the habit of questioning whether a methodology was actually fit for the audience in front of us. In oncology, that question matters more than almost anywhere else. Oncologists are time-poor, scientifically sophisticated, and deeply sceptical of commercial messaging. They respond to evidence, not positioning language. A survey instrument written by someone without clinical context will produce noise, not signal.

The complexity compounds when you factor in how oncology prescribing actually works. Decisions are rarely made by a single physician. Tumour boards, multidisciplinary teams, institutional protocols, and NCCN guidelines all shape what gets prescribed and when. Your research design needs to account for that decision architecture, not assume a simple one-to-one relationship between a doctor and a treatment choice.

If you want a broader view of how market research fits into commercial strategy across different sectors, the resources at The Marketing Juice market research hub cover the full range of methodologies and decision frameworks worth understanding before you commission anything in a specialised category like this one.

The Three Research Audiences Most Teams Underserve

Most oncology market research budgets are weighted heavily toward HCP research. That is understandable. Oncologists are the prescribers. But the research picture is incomplete if it stops there.

Patients and caregivers are distinct audiences with distinct needs, and conflating them is a common error. A patient living with metastatic breast cancer has a different relationship with treatment information than a caregiver managing a parent’s lung cancer experience. The emotional register is different, the decision-making role is different, and the barriers to engagement are different. Research that lumps these two groups together produces findings that accurately represent neither.

Patient research in oncology also requires careful ethical handling. Recruitment, consent, and the emotional weight of participation need to be managed with more care than a standard consumer survey. I have seen teams cut corners here not out of bad intent, but because they applied a consumer research template to a context it was never designed for. The quality of the insight suffers accordingly.

Payers are consistently under-researched relative to their commercial influence. In oncology, where treatment costs can run to tens of thousands per cycle, payer decisions about formulary placement, step therapy requirements, and prior authorisation criteria can determine whether a product achieves its commercial potential regardless of how well it performs clinically. Payer research requires different recruitment, different question design, and a different analytical lens. It is not a footnote to HCP research. In many oncology launches, it is the most commercially critical piece of intelligence you can gather.

Nurses and advanced practice providers are a third audience that gets less attention than it deserves. In oncology settings, nurses and APPs often have significant influence over patient education, adherence support, and in some cases treatment selection. If your research only talks to oncologists, you are missing part of the decision-making picture.

Qualitative Methods in Oncology: What Works and What Wastes Budget

Qualitative research in oncology is where a lot of budget gets spent and a lot of insight gets lost. The methodological choices matter.

In-depth interviews with oncologists remain the gold standard for exploratory work. You get depth, nuance, and the ability to follow unexpected threads. The challenge is recruitment. Oncologists are among the most difficult specialist audiences to access. Response rates are low, scheduling is difficult, and the incentive required to secure participation is significant. Any research plan that assumes easy access to this audience is not grounded in operational reality.

Focus groups in oncology require more care in design than in most therapeutic areas. The dynamics of a room full of oncologists can suppress minority views, particularly around topics where there is a dominant clinical consensus. A well-designed focus group can surface shared mental models and reveal how clinicians discuss treatment options among themselves. A poorly designed one produces groupthink dressed up as insight. I have written separately about focus group research methods and the structural choices that determine whether you get genuine debate or polite agreement.

Advisory boards are widely used in oncology and are often confused with market research. They are not the same thing. An advisory board is a relationship-building and educational forum. It can generate useful intelligence as a byproduct, but it is not designed for unbiased insight generation. If you are treating advisory board outputs as market research findings, you are working with a compromised data set.

Ethnographic approaches, including observational research in clinical settings and digital ethnography in patient communities, are underused in oncology and often produce more actionable insight than structured interviews. Watching how a multidisciplinary team actually discusses a treatment decision tells you more than asking an oncologist to describe how they make decisions in the abstract.

Quantitative Research: The Sample Size Problem Nobody Talks About

Oncology is a small-numbers world. The population of oncologists in any given sub-specialty is limited. The population of patients with a specific biomarker-defined tumour type can be smaller still. This creates a fundamental tension with quantitative research, which relies on sample sizes large enough to produce statistically meaningful results.

I spent time at iProspect managing campaigns where we were working with high-volume data sets across broad consumer audiences. The statistical confidence you can achieve in that environment is genuinely different from what is possible when your total addressable audience is 800 specialist oncologists nationally. That does not mean quantitative research in oncology is not worth doing. It means you need to be honest about what it can and cannot tell you.

A survey of 60 oncologists in a specific sub-specialty can tell you directional things. It cannot tell you with statistical confidence that 73% of prescribers prefer a particular dosing schedule. When I was judging at the Effie Awards, one of the patterns I noticed in weaker entries was the tendency to present directional data as definitive evidence. In oncology market research, that habit is particularly dangerous because the findings feed into launch decisions worth hundreds of millions of dollars.

The honest approach is to design quantitative and qualitative research so they complement each other. Use qualitative methods to generate hypotheses and understand the landscape. Use quantitative methods to test those hypotheses at the scale that the audience size permits, and be transparent about the confidence levels you can reasonably claim.

This connects to a broader point about how research should be used to drive decisions rather than validate assumptions. The approach to pain point research that works in marketing services is structurally similar to what works in oncology: you need to understand what is actually driving behaviour, not what respondents say is driving it, and the gap between those two things is often where the most useful insight lives.

Competitive Intelligence in Oncology: The Pipeline Problem

Oncology pipelines move fast. A competitive landscape that looked stable when you started your research programme can look entirely different by the time you reach launch. This is not a minor operational inconvenience. It is a strategic risk that needs to be built into how you structure your research calendar.

One of the things I learned early in agency life, back when I was building tools and processes from scratch because there was no budget for anything else, was that the most valuable competitive intelligence is not the snapshot, it is the trend. A single audit of the competitive landscape tells you where things are. A series of audits over time tells you where things are going. In oncology, where trial readouts, regulatory decisions, and label updates can shift competitive dynamics within a quarter, the trend is what matters.

Primary competitive intelligence in oncology comes from multiple sources: congress presentations, published trial data, ClinicalTrials.gov, prescribing data, and direct HCP research about competitive perceptions. Secondary intelligence comes from analyst reports, pipeline databases, and regulatory filings. Both are necessary. Neither is sufficient on its own.

There is also a category of intelligence that sits in less obvious places. Online communities where oncologists discuss clinical cases, patient advocacy forums, and even social listening across professional networks can surface early signals about competitive positioning and unmet need. This is territory that overlaps with what I have described elsewhere as grey market research, the kind of intelligence gathering that does not fit neatly into a commissioned research brief but often produces the most commercially relevant findings.

The missing link in most marketing strategy is the failure to connect research findings to actual commercial decisions. In oncology competitive intelligence, that failure often manifests as teams that know a great deal about the competitive landscape but have not translated that knowledge into clear implications for positioning, messaging, or launch timing.

Search Intelligence as an Oncology Research Tool

Search data is one of the most underused intelligence sources in oncology market research. The search behaviour of oncologists, patients, and caregivers reveals what questions are actually being asked, at what volume, and in what language. That is different from what a survey respondent says they want to know, and the difference is commercially significant.

When I was running paid search at scale, one of the consistent lessons was that keyword data tells you what people are actively seeking, not what they claim to be interested in when asked directly. In oncology, where the gap between clinical language and patient language can be enormous, search intelligence helps you understand how different audiences actually frame their questions about treatment, side effects, and disease management.

Search intelligence can also reveal unmet informational needs that primary research misses. If a high volume of searches are clustering around a specific question about your therapy area that existing content does not answer well, that is both a content opportunity and a market research signal about what matters to your audience. The full methodology for applying this kind of analysis is covered in the piece on search engine marketing intelligence, which is worth reading alongside any primary research planning in a specialist category like oncology.

Translating Research Into Commercial Decisions

The most common failure mode in oncology market research is not methodological. It is translational. Teams commission rigorous research, produce thorough reports, and then fail to connect the findings to the decisions that actually need to be made.

I have sat in enough strategy sessions to recognise the pattern. The research team presents findings. The commercial team nods. The brand team asks a few questions. And then everyone goes back to doing roughly what they were planning to do before the research was commissioned. The research did not change anything because nobody defined upfront what decisions it was supposed to inform.

This is a process failure, not a research failure. Before you commission any oncology market research, you should be able to answer three questions. What decision are we trying to make? What would we need to find out to make that decision with confidence? And what would we do differently depending on what the research tells us? If you cannot answer all three, the research is not ready to be commissioned.

The same discipline applies when you are thinking about how to profile and prioritise the audiences your research needs to reach. The frameworks used in ICP scoring for B2B contexts translate usefully into oncology audience prioritisation, particularly when you are trying to decide which physician segments to focus on in a crowded specialty with limited research budget.

When research findings do not translate into decisions, it is worth asking whether the research design was solving the right problem. In oncology, where the commercial and clinical complexity is high, there is a tendency to commission research that answers interesting questions rather than decision-critical ones. Interesting findings fill decks. Decision-critical findings change plans.

The same principle applies when oncology teams are evaluating their broader strategic position. A rigorous SWOT-based strategy alignment process can help connect market research outputs to the commercial decisions they are supposed to inform, particularly in organisations where research, medical, and commercial functions operate in silos.

What Good Oncology Market Research Actually Looks Like

Good oncology market research is not defined by the sophistication of the methodology or the thickness of the report. It is defined by whether it changes what the team does.

That means it needs to be designed around decisions from the start. It needs to use methodologies that are genuinely fit for the audience, not borrowed from adjacent categories where they happen to work. It needs to be honest about the limits of what small-sample quantitative data can tell you. And it needs a clear translation process that connects findings to actions before the report is even written.

In a category where the science moves fast, the competitive landscape shifts regularly, and the stakes of getting it wrong are high, that discipline is not optional. It is the baseline.

There is more on building research programmes that actually drive decisions across the full range of market research methods and frameworks at The Marketing Juice market research hub, including approaches that work for both specialist and general marketing contexts.

About the Author

Keith Lacy is a marketing strategist and former agency CEO with 20+ years of experience across agency leadership, performance marketing, and commercial strategy. He writes The Marketing Juice to cut through the noise and share what works.

Frequently Asked Questions